Products pipeline

Attention: open in a new window. PDFPrintE-mail

There are no translations available.

Cardio3 BioSciences is developing the breakthrough proprietary Cardiopoiesis platform, which is based on fundamental research and proprietary technology from Mayo Clinic. This novel platform is designed to drive the differentiation of multipotent stem cells into new cardiac progenitor cells. Based on this Cardiopoiesis platform, the Company has generated a pipeline of product candidates and research programmes targeting heart failure (HF) and acute myocardial infaction (AMI).

 

graphe-cardio3

click-on-image

image-titre-autologus

C3BS-CQR-1 (C-Cure®)  

C-Cure is Cardio3 BioSciences' most advanced product candidate based on the Cardiopoiesis platform. C-Cure is being developed for HF indications. C-Cure consists of a patient's own cells harvested from bone marrow, treated with the Cardiopoietic cocktail and then re-injected into the heart. It is designed to produce new autologous heart muscle cells which behave identically to those lost in infarction without carrying the risk of rejection.

 

 

Modes of Action

C-Cure has two modes of action:

 

  • directly through the proliferation, engrafment and terminal differentiation of the injected cells; and
  • indirectly through the beneficial effect of the factors excreted by the transplanted cells on the host's own resident cardiac stem cells.

 

 

Positive Phase II results

In the Phase II clinical trial, heart failure patients treated with C-Cure showed a highly significant 18.1% relative improvement of Left Ventricular Ejection Fraction (a measure of heart function) versus baseline compared to a relative improvement of 3.6% versus baseline for the control group who were treated with standard of care alone. Certain other measures of improvement such as the ventricular volumes or measures of ventricular remodelling were also in favour of the C-Cure group. In addition, patients in the C-Cure group had a statistically significantly better exercise capacity as measured by a standard test called the "six minute walking distance test": the C-Cure group's walking distance improved over the control group by 73 meters. On the basis of these positive results, Cardio3 BioSciences intends to apply for the required national clinical trial authorizations to carry out a Phase III program starting H1 2012. With C-Cure, Cardio3 BioSciences aims to become the first company with an approved regenerative product for ischemic HF.

 

See more details on this Press Release. 

Further details on Study Summary

 

image-titre-protein


C3BS-GQR-1

Drawing on its understanding of the processes involved in Cardiopoiesis, Cardio3 BioSciences has formulated C3BS-GQR-1, a protein-based product candidate which is aimed at protecting heart tissue from acute injury and promoting activation of resident cardiac stem cells in an AMI setting. A pre-clinical proof-of-concept study in swine showed a 65% decrease in scar size at six weeks post infarction compared to a 25% decrease in scar size following a placebo injection. Cardio3 BioSciences intends to further develop C3BS-GQR-1, including encapsulating the factors in matrices to achieve sustained release over the desired two-week period. Additional preclinical development including confirmatory animal trial and toxicity studies will be conducted in 2012. Cardio3 BioSciences intends to seek to partner this programme to a stent manufacturer or pharmaceutical company once the programme is sufficiently advanced. 


See more details on this Press Release.

 

C3BS-GQR-2

C3BS-GQR-2 aims to stimulate the patient's resident CSCs in both AMI and HF setting. Cardio3 BioSciences has compared the secretome (the group of factors) secreted by cardiopoietic and undifferentiated cells to identify those that contribute more to CSC activation.

 

image-titre-medical


C-CATH

Cardio3 BioSciences is developing C-Cath, a proprietary catheter designed to maximize the delivery efficiency of regenerative therapeutics to the heart. C-Cath is an intra-myocardial delivery catheter, designed to reduce risk of myocardium perforation, increase needle stability and deliver enhanced fluid dynamics to improve retention. Efforts to set up a quality management system that is conform to ISO 13485:2003 are completed. Final design, that addressed the most recent comments received from key opinion leaders in terms of the ease of handling of the device, is also completed. The submission for CE-marking was done on November 21st 2011.
 


C-Cure²

C-Cure² utilizes another source of mesenchymal stem cells, the adipose tissue, to provide larger number of stem cells for cardiac programming

Allo-Cure

Allo-Cure is an allogeneic cell based therapy for the treatment of ischemic congestive heart failure, and of acute myocardial infarction, using the core platform of cardiopoietic programming

G-Cure

G-Cure is a protein based approach using the secretome of cardiopoietic cells to stimulate cardiac stem cells activation and maturation

C Cath

Cardio3 BioSciences is also developing  a proprietary injection catheter  for C-Cure that will increase cell retention and facilitate accurate injections. This system is called C-Cath.

The catheter C-Cath is based on our expertise in medical device, our in-depth knowledge of the cell biology, and the impact of cell retention at the site of injection on efficacy of a cell therapy. Cell retention is notoriously low with existing injection catheters due to a number of factors such as characteristics of the needle, needle orientation, speed and depth of injection, etc..

C-Cath is designed to take into account organ tissue structure and properties to maximize patient's safety, improve performance and increase user confidence during the injection procedure.

C-Cath would potentially be used with C-Cure and further Cardio3BioSciences products in development such as allogeneic and protein therapeutics. C-Cath would also present an attractive delivery technology for a range of therapies in the cardiovascular and potentially other fields.

© 2009 Cardio 3 Biosciences

A concept of Expansion